Sana Biotechnology

Sana Biotechnology's shares hit a 52-week low of $2.29, down 81% from its high. The company faces cash burn concerns despite a healthy balance sheet. The FDA fast-tracked Sana's SC291 therapy for lupus, with initial data expected in 2025. Sana restructured its pipeline, prioritizing Type 1 diabetes and B-cell autoimmune disease programs. Analysts have mixed ratings, with H.C. Wainwright maintaining a Buy and JMP Securities downgrading to Market Perform. CFO Nathan Hardy will step down in October 2024, and Dhaval Patel has been appointed as the new Chief Scientific Officer.

The FDA investigates bluebird bio's Skysona over hematologic malignancies. REGENXBIO starts phase 3 AFFINITY DUCHENNE trial for RGX-202 in DMD. Genethon and Hansa Biopharma initiate phase 2 trial for Crigler–Najjar syndrome. Sana Biotechnology's SC291 gets fast track designation for SLE. Roche to acquire Poseida Therapeutics. Exegenesis Bio's EXG110 receives orphan drug designation for Fabry disease. NorthX Biologics partners with Amarna Therapeutics for Nimvec AM510.

Sana Biotechnology's SC291, a CD19-directed, hypoimmune (HIP)-modified allogeneic CAR T therapy, received FDA fast track designation for relapsed/refractory systemic lupus erythematosus (SLE). SC291, designed as an off-the-shelf treatment, is under investigation in the GLEAM trial, aiming to address unmet needs in SLE treatment. Initial data from the trial are expected in 2025.

Pomerantz LLP investigates claims of securities fraud by Sana Biotechnology, Inc., after the company suspended development of its oncology and glial progenitor cell programs, causing a 9.84% stock price drop.

Pomerantz LLP investigates claims on behalf of Sana Biotechnology, Inc. (NASDAQ: SANA) investors for potential securities fraud. Sana's stock price fell $0.37 (9.84%) to $3.39 after announcing suspension of development for SC291 and SC379 programs.

The FDA granted Fast Track Designation to Sana Biotechnology's SC291 CAR T-cell therapy for relapsed/refractory SLE, including extrarenal lupus and lupus nephritis. SC291, a HIP-modified allogeneic CAR T therapy, is being evaluated in the phase 1 GLEAM trial, with initial data expected in 2025. The trial assesses safety, tolerability, and disease activity changes. Recent lupus treatment updates were presented at the ACR Convergence 2024, including the 3 PHOENYCS GO trial, which met its primary endpoint of BICLA response at week 48 with Dapirolizumab Pegol.

Sana Biotechnology receives Fast Track designation for SC291, an allogeneic CAR T therapy targeting CD19 in relapsed/refractory systemic lupus erythematosus. The GLEAM trial, evaluating SC291 in B-cell mediated autoimmune diseases, is enrolling patients with initial data expected in 2025.

Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.

A form includes dropdowns for selecting a state, zip code, and country, with California pre-selected as the default state and the United States as the default country.